Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Mizuho Expands its Healthcare Team with the Hiring of Senior Biotechnology Research Analyst Mara Goldstein
-
Rambler Metals & Mining PLC Announces Convertible Loan Note Financing
-
A slippery trade: oil slump proves bears right
-
Long Island Capital Alliance to Hold Cannabis Capital Forum on December 7, 2018
-
Taiwan Liposome Company (TLC) Prices 3.75M ADS IPO at $5.80/ADS
-
TLC Announces Pricing of Initial Public Offering of American Depositary Shares (ADSs) on Nasdaq
-
Rambler Metals & Mining PLC Announces Q3 2018 Financial Results
-
FinTech Acquisition Corp. III Announces Completion of $345,000,000 Initial Public Offering, Including Full Exercise of Over-Allotment Option
-
FinTech Acquisition Corp. III Announces Completion of $345,000,000 Initial Public Offering, Including Full Exercise of Over-Allotment Option
-
Northern Dynasty Minerals (NAK) PT Raised to $1.10 at Cantor Fitzgerald
-
NYSE’s Top DMM – GTS – Takes Stake in Minority Broker-Dealer
-
Rodin® Global Property Trust, Inc. Announces Acquisition of Dallas Fort-Worth Industrial Building
-
UPDATE: Cantor Fitzgerald Upgrades Northern Dynasty Minerals (NAK) to Spec. Buy
-
FinTech Acquisition Corp. III (FTACU) Prices 30M Unit Upsized IPO at $10/Unit
-
FinTech Acquisition Corp. III Announces Pricing of Upsized $300,000,000 Initial Public Offering
-
FinTech Acquisition Corp. III Announces Pricing of Upsized $300,000,000 Initial Public Offering
-
BNP Paribas and GTS Extend Strategic Collaboration into US Equities
-
uniQure BV (QURE) PT Raised to $65 at Cantor Fitzgerald
-
Cantor Fitzgerald Starts Ovid Therapeutics Inc (OVID) at Overweight
-
Cantor Fitzgerald Starts Otonomy (OTIC) at Overweight
-
Cantor Fitzgerald Starts Denali Therapeutics Inc. (DNLI) at Overweight
-
Cantor Fitzgerald Starts Axsome Therapeutics (AXSM) at Overweight
-
Cantor Fitzgerald Starts Aptinyx (APTX) at Overweight
-
Orchid Island Capital Announces November 2018 Monthly Dividend and October 31, 2018 RMBS Portfolio Characteristics
-
Cantor Fitzgerald Downgrades Five Star Quality Care (FVE) to Neutral
-
Contango ORE, Inc. Announces Annual Meeting of Stockholders Results, Quarterly Results and Retains Cantor Fitzgerald and Petrie Partners to Advise on Strategic Alternatives
-
Ideanomics Appoints New Officers and Directors
-
Cantor Fitzgerald Starts ProQR Therapeutics N.V. (PRQR) at Overweight
-
BGC Partners (BGCP) Announces Spin-Off of Newmark (NMRK)
-
BGC Partners Announces Spin-Off of Newmark
-
Amarin (AMRN) Mineral Oil Concerns Not an Oil Spill - Cantor Fitzgerald
-
Albireo Reports Third Quarter 2018 Financial Results
-
EMX Derivatives Exchange Expands Management Team; Former BitMEX Head of Support to open Hong Kong Office
-
PTC Therapeutics (PTCT) PT Lowered to $61 at Cantor Fitzgerald
-
Cantor Fitzgerald Downgrades Pacific Biosciences of California (PACB) to Neutral
-
Denison Reports Results from Q3 2018
-
Colony Credit Real Estate Announces Appointment of New Chief Financial Officer and Chief Accounting Officer
-
Matlin & Partners Acquisition Corporation and U.S. Well Services, LLC Complete Business Combination
-
AcelRx Pharma (ACRX) Prices 12.698M Share Common Offering at $3.15/Sh
-
BioDelivery Sciences International (BDSI) PT Raised to $5 at Cantor Fitzgerald
-
AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Omeros (OMER) Prices $210 Million Offering of Convertible Senior Notes Due 2023
-
AcelRx Pharma (ACRX) Announces Proposed Common Offering
-
Omeros Announces Pricing of $210 Million Offering of Convertible Senior Notes Due 2023
-
AcelRx Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Sarepta Therapeutics (SRPT) Prices 3.187M Share Common Offering at $131/Sh
-
Sarepta Therapeutics Announces Pricing of $500,000,000 Public Offering of Common Stock
-
Omeros (OMER) Proposed $210 Million Offering of Convertible Senior Notes Due 2023
-
Omeros Announces Proposed $210 Million Offering of Convertible Senior Notes Due 2023
-
Westwater Resources Reports Third Quarter 2018 Operating Results

